Cargando…

2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia

BACKGROUND: Increasing evidence suggests that daptomycin (DAP) demonstrates in vitro synergy in combination with other anti-staphylococcal agents, including ceftaroline (CPT) and oxacillin (OXA), against MRSA. Nevertheless, optimal combinations remain undefined. Here, our objective was to compare DA...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouchard, Jeannette, Jones, Chelsea, Kline, Ellen, Oleksiuk, Louise-Marie, Shields, Ryan K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254037/
http://dx.doi.org/10.1093/ofid/ofy210.2056
_version_ 1783373632030900224
author Bouchard, Jeannette
Jones, Chelsea
Kline, Ellen
Oleksiuk, Louise-Marie
Shields, Ryan K
author_facet Bouchard, Jeannette
Jones, Chelsea
Kline, Ellen
Oleksiuk, Louise-Marie
Shields, Ryan K
author_sort Bouchard, Jeannette
collection PubMed
description BACKGROUND: Increasing evidence suggests that daptomycin (DAP) demonstrates in vitro synergy in combination with other anti-staphylococcal agents, including ceftaroline (CPT) and oxacillin (OXA), against MRSA. Nevertheless, optimal combinations remain undefined. Here, our objective was to compare DAP in combination with CPT or OXA against MRSA bloodstream isolates collected from patients with persistent bacteremia despite >7 days of vancomycin treatment. METHODS: Minimum inhibitory concentrations (MICs) for DAP, CPT, and OXA were determined in duplicate by reference broth microdilution methods. We used time-kill analyses (TKA) to test free peak concentrations (fC(max)) of DAP (8 µg/mL), CPT (16 µg/mL), and OXA (4 µg/mL) alone and in combination against 1 × 10(8) CFU/mL to simulate high-inocula infections. Bactericidal and synergistic activity were defined as a ≥3-log(10) decrease in CFU/mL and >2-log(10) decrease in CFU/mL in combination compared with the most active single agent, respectively, at 24 hours. RESULTS: A representative isolate was selected from 12 patients with persistent MRSA bacteremia. Median (range) MICs were 0.5 (0.5–1), 0.5 (0.5–1), and 64 (64–≥128) µg/mL for DAP, CPT, and OXA, respectively. By TKA (n = 5 isolates), median log-kills were −3.81, −1.90, and +1.99 log(10)CFU/mL for DAP, CPT, OXA, respectively. Corresponding rates of bactericidal activity were 80%, 20%, and 0%, respectively. In combination, median log-kills were −7.83 and −4.82 log(10)CFU/mL for DAP+CPT and DAP+OXA, respectively (P = 0.111; Figure 1). DAP was synergistic in combination with CPT or OXA against 80% and 60% of isolates, respectively. Median log-kills in combination with CPT or OXA were higher than DAP alone (P = 0.003 and P = 0.0497, respectively). At 24 hours, colony counts were below the lower limit of detection (50 CFU/mL) against 60% and 20% of isolates exposed to DAP+CPT or DAP+OXA, respectively. CONCLUSION: Among persistent MRSA bloodstream isolates, combinations of DAP + CPT or OXA demonstrates synergy and statistically greater killing effects in vitro at fCmax concentrations than DAP alone. Log-kills were greatest with DAP+CPT, which merits further validation in pre-clinical models. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6254037
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62540372018-11-28 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia Bouchard, Jeannette Jones, Chelsea Kline, Ellen Oleksiuk, Louise-Marie Shields, Ryan K Open Forum Infect Dis Abstracts BACKGROUND: Increasing evidence suggests that daptomycin (DAP) demonstrates in vitro synergy in combination with other anti-staphylococcal agents, including ceftaroline (CPT) and oxacillin (OXA), against MRSA. Nevertheless, optimal combinations remain undefined. Here, our objective was to compare DAP in combination with CPT or OXA against MRSA bloodstream isolates collected from patients with persistent bacteremia despite >7 days of vancomycin treatment. METHODS: Minimum inhibitory concentrations (MICs) for DAP, CPT, and OXA were determined in duplicate by reference broth microdilution methods. We used time-kill analyses (TKA) to test free peak concentrations (fC(max)) of DAP (8 µg/mL), CPT (16 µg/mL), and OXA (4 µg/mL) alone and in combination against 1 × 10(8) CFU/mL to simulate high-inocula infections. Bactericidal and synergistic activity were defined as a ≥3-log(10) decrease in CFU/mL and >2-log(10) decrease in CFU/mL in combination compared with the most active single agent, respectively, at 24 hours. RESULTS: A representative isolate was selected from 12 patients with persistent MRSA bacteremia. Median (range) MICs were 0.5 (0.5–1), 0.5 (0.5–1), and 64 (64–≥128) µg/mL for DAP, CPT, and OXA, respectively. By TKA (n = 5 isolates), median log-kills were −3.81, −1.90, and +1.99 log(10)CFU/mL for DAP, CPT, OXA, respectively. Corresponding rates of bactericidal activity were 80%, 20%, and 0%, respectively. In combination, median log-kills were −7.83 and −4.82 log(10)CFU/mL for DAP+CPT and DAP+OXA, respectively (P = 0.111; Figure 1). DAP was synergistic in combination with CPT or OXA against 80% and 60% of isolates, respectively. Median log-kills in combination with CPT or OXA were higher than DAP alone (P = 0.003 and P = 0.0497, respectively). At 24 hours, colony counts were below the lower limit of detection (50 CFU/mL) against 60% and 20% of isolates exposed to DAP+CPT or DAP+OXA, respectively. CONCLUSION: Among persistent MRSA bloodstream isolates, combinations of DAP + CPT or OXA demonstrates synergy and statistically greater killing effects in vitro at fCmax concentrations than DAP alone. Log-kills were greatest with DAP+CPT, which merits further validation in pre-clinical models. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6254037/ http://dx.doi.org/10.1093/ofid/ofy210.2056 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Bouchard, Jeannette
Jones, Chelsea
Kline, Ellen
Oleksiuk, Louise-Marie
Shields, Ryan K
2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia
title 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia
title_full 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia
title_fullStr 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia
title_full_unstemmed 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia
title_short 2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia
title_sort 2403. comparison of daptomycin combination therapy with ceftaroline or oxacillin against methicillin-resistant staphylococcus aureus (mrsa) isolates causing persistent bacteremia
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254037/
http://dx.doi.org/10.1093/ofid/ofy210.2056
work_keys_str_mv AT bouchardjeannette 2403comparisonofdaptomycincombinationtherapywithceftarolineoroxacillinagainstmethicillinresistantstaphylococcusaureusmrsaisolatescausingpersistentbacteremia
AT joneschelsea 2403comparisonofdaptomycincombinationtherapywithceftarolineoroxacillinagainstmethicillinresistantstaphylococcusaureusmrsaisolatescausingpersistentbacteremia
AT klineellen 2403comparisonofdaptomycincombinationtherapywithceftarolineoroxacillinagainstmethicillinresistantstaphylococcusaureusmrsaisolatescausingpersistentbacteremia
AT oleksiuklouisemarie 2403comparisonofdaptomycincombinationtherapywithceftarolineoroxacillinagainstmethicillinresistantstaphylococcusaureusmrsaisolatescausingpersistentbacteremia
AT shieldsryank 2403comparisonofdaptomycincombinationtherapywithceftarolineoroxacillinagainstmethicillinresistantstaphylococcusaureusmrsaisolatescausingpersistentbacteremia